Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, a Phase I trial product, an oral toll-like receptor 7 for the treatment of hepatitis C and cancer. The company was formerly known as Scriptgen Pharmaceuticals, Inc. and changed its name to Anadys Pharmaceuticals, Inc. in May 2000. Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ANDS